The promise of psychedelic medicine in psychiatry

Psychedelic medicine is getting closer to regulatory approval in psychiatry, with trials for difficult-to-treat depression and anxiety under way. After long stigma and political backlash, compounds derived from psychoactive substances such as psilocybin and LSD are now part of closely watched psychiatric drug development, and early results suggest benefits where standard therapies do not work well. The clinical momentum is framed as part of translational progress, moving psychedelic research from experimental interest toward broader clinical use as pivotal studies generate the evidence needed for approval.